<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00394485</url>
  </required_header>
  <id_info>
    <org_study_id>OPPI-MPTA-COPD-1</org_study_id>
    <nct_id>NCT00394485</nct_id>
  </id_info>
  <brief_title>Tiotropium + Procaterol vs Tiotropium + Placebo in COPD Patients</brief_title>
  <official_title>A Randomized Crossover Trial Comparing the Efficacy and Safety of Tiotropium + Procaterol vs. Tiotropium + Placebo in Moderate COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical, Inc., Philippines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Pharmaceutical, Inc., Philippines</source>
  <brief_summary>
    <textblock>
      Study compares the efficacy and safety of tiotropium + a beta agonist (procaterol) vs.
      tiotropium alone among patients with moderate chronic obstructive pulmonary disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to determine the efficacy and safety of tiotropium plus procaterol in
      comparison to tiotropium plus placebo in Filipino patients seen in Manila, with moderate
      COPD.

      After a 1-week wash-out period, 6-minute walk test, and St. George's Respiratory
      Questionnaire (SGRQ) will then be administered prior to a run-in period of 1 week wherein all
      patients will be started on tiotropium alone. The patients will then be randomly allocated to
      either of the two arms for a two-week treatment, followed by one week washout, and
      crossed-over to the other treatment for another two weeks. The procaterol or placebo dose is
      given 2 hrs after the tiotropium dose.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty in recruting patients
  </why_stopped>
  <start_date>May 2006</start_date>
  <completion_date>April 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>[Efficacy] Improvement spirometry (FEV1, FVC, FEV1/FVC, 6 MWD, TDI) and SGRQ at 2 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>[Safety] HR (Heart Rate) and BP (Blood Pressure)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse reactions and changes</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procaterol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. GOLD criteria for moderate COPD (post-bronchodilator)

               -  FEV1/FVC &lt; 70%

               -  50% â‰¤ FEV1 &lt; 80% predicted

               -  With or without symptoms

          2. Willing to undergo the treatment protocol with signed informed consent

        Exclusion Criteria:

          1. Exacerbation within 1 month prior to run-in period

          2. Significant hypoxemia and/or desaturation at rest and during exercise.

          3. Significant cardiac, renal, or other systemic disease

          4. History of adverse reaction to any of the two test drugs (tiotropium and procaterol)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abundio A Balgos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of the Philippines College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Philippine General Hospital</name>
      <address>
        <city>Manila</city>
        <state>National Capital Region</state>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2006</study_first_submitted>
  <study_first_submitted_qc>October 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2006</study_first_posted>
  <last_update_submitted>December 15, 2009</last_update_submitted>
  <last_update_submitted_qc>December 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Co, Benjamin, Medical Director</name_title>
    <organization>Otsuka Pharmaceutical, Inc., Philippines</organization>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Procaterol</keyword>
  <keyword>Tiotropium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Procaterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

